- Oral presentation
- Open Access
Multifunctional perfluorooctylbromide alginate microcapsules for monitoring of mesenchymal stem cell delivery using CT and MRI
© Fu et al; licensee BioMed Central Ltd. 2009
- Published: 28 January 2009
- Mesenchymal Stem Cell
- Peripheral Arterial Disease
- Human MSCs
- Stem Cell Delivery
- Peripheral Arterial Disease Patient
Many patients with peripheral arterial disease (PAD) cannot undergo conventional medical or surgical therapy due to the extent or severity of atherosclerotic disease. Stem cell therapy has shown promising results as an angiogenic therapy in PAD patients. However, the poor survival of transplanted cells due to early immunodestruction and the inability to noninvasively monitor and track the distribution and proliferation of transplanted cells hinders stem cell therapeutic efficacy. We present here a multifunctional mesenchymal stem cell (MSC) microencapsulation and trafficking method utilizing perfluorooctylbromide (PFOB) incorporated alginate-poly-L-lysine-alginate microcapsules (PFOB Caps) for MSC delivery and noninvasive engraftment tracking using clinical X-ray and MR imaging equipment.
Microencapsulation of bone marrow-derived rabbit or human MSCs (1.5 × 106cells/ml) were performed by extruding a PFOB-impregnated 2% (w/v) alginate solution from a syringe pump in conjunction with an electrostatic droplet generator, followed by cross linking with poly-L-lysine to form X-ray- and MRI-visible microcapsules. MSCs viability was examined and compared between unlabeled capsules and PFOB Caps. Using 19F MRI and rotational angiograms reconstructed into CT-like images, the minimum detectable concentration was determined in phantoms using standard clinical imaging systems. X-ray delivery and tracking of intramuscular injections of PFOB Caps (~5000 capsules/injection) was assessed in a rabbit PAD model.
By adding PFOB, a dual contrast agent and oxygen carrier, to alginate microcapsules, we have demonstrated the enhanced viability of MSCs within PFOB Caps, and the ability to deliver and track engraftment of stem cells using multiple conventional clinical imaging systems in vivo.
This article is published under license to BioMed Central Ltd.